SOPH · SOPHiA Genetics SA
United States · RS rating 79 · As of 2026-11-03
| Price | 6.91 USD |
|---|---|
| 1-day change | -2.8% |
| RS rating (overall / 1M / 3M / 12M) | 79 / 26 / 82 / 79 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 41 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +3.6% |
| Sales growth Q/Q | +11.5% |
| Distance from 52-week high | +22.5% |
| Market cap (USD) | $349.0M |